Taj Pharmaceuticals Ltd.

Olanzapine

CAS No. : 132539-06-1

Systematic (IUPAC) name

2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; Lanzac; Zyprexa

Chemical data

Molecular Formula C17H20N4S
Molecular Weight 312.43
CAS Registry Number 132539-06-1
Formula C17H20N4S
Mol. mass 312.439
SMILES eMolecules & PubChem



Pharmacokinetic data

Bioavailability ?
Metabolism Hepatic
Half life 21–54 hours

DOSAGE

The usual oral dose for treating schizophrenia is 10 mg once daily. Therapy is initiated with 5-10 mg/day and the dose may be increased by 5 mg a day in weekly intervals. Doses greater than 10 mg daily have not been shown to be more effective than 10 mg daily. The safety and efficacy of doses greater than 20 mg daily have not been evaluated.

Treatment of bipolar disorder usually is initiated with oral doses of 10-15 mg once daily. The dose may be increased by 5 mg daily at 24 hour intervals. Doses greater than 20 mg daily have not been evaluated. In clinical trials, doses of 5-20 mg daily were effective.

The usual dose for treating agitation due to schizophrenia or bipolar disorder is 10 mg administered by intramuscular injection. Additional 10 mg doses may be administered, but the efficacy of total daily doses greater than 30 mg daily have not been adequately evaluated.

Olanzapine is eliminated from the body more quickly in young people than in older (over age 60) individuals, in men than in women, and in smokers faster than in non-smokers. Dosage adjustments may be needed based upon individual patient characteristics.
Information Associated with Product:

SIDE EFFECTS

Olanzapine may cause side effects.

* drowsiness
* dizziness
* restlessness
* unusual behavior
* depression
* difficulty falling asleep or staying asleep

Taj Pharmaceuticals Ltd.
Olanzapine
CAS NO- 132539-06-1

* weakness
* difficulty walking
* constipation
* weight gain
* dry mouth
* pain in arms, legs, back, or joints

Some side effects can be serious.

* seizures
* changes in vision
* swelling of the arms, hands, feet, ankles, or lower legs
* unusual movements of your face or body that you cannot control
* fever
* very stiff muscles
* excess sweating
* fast or irregular heartbeat
* rash
* hives
* difficulty breathing or swallowing

PRECAUTIONS

precaution should be used in patients with heart disease because the drug may cause blood pressure to fall too low resulting in dizziness, rapid heartbeats, or fainting. Olanzapine should be used carefully in people with known seizure disorders since olanzapine may alter properties of the brain making seizures occur more easily. People with liver disease should have their liver function monitored regularly while taking olanzapine. Women who are pregnant or breast-feeding should not take olanzapine. People with phenylketonuria, a disorder in which the body is unable to metabolize a protein called phenylalanine, should avoid olanzapine disintegrating tablets, because this form of the drug contains phenylalanine.
Before taking olanzapine, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This medication should not be used if you have certain medical conditions. Before using this medicine, consult your doctor or pharmacist if you have a history of the following: neuroleptic malignant syndrome (see also Side Effects section). Before using this medication, tell your doctor or pharmacist your medical history, especially of: liver problems, low blood pressure, breast cancer, stroke, dementia, Alzheimer's disease, seizures, prostate problems, glaucoma (narrow angle type), intestinal disease, difficulty swallowing, tardive dyskinesia (see also Side Effects section), smoking. (See also Side Effects section.) Also tell your doctor or pharmacist if either you or a family member has a history of the following: diabetes, heart disease, high blood cholesterol/triglyceride levels, high blood pressure, obesity. This drug may make you dizzy or drowsy; use caution engaging in activities requiring alertness such as driving or using machinery. Avoid alcoholic beverages. This medication can make you prone to heat stroke. Avoid activities that might cause you to overheat (e.g., doing strenuous work, exercising in hot weather, or using hot tubs). Caution is advised when using this drug in the elderly because they may be more sensitive to its effects, especially dizziness, drowsiness, or seizures. This medication should be used only when clearly needed during pregnancy. Discuss the risks and benefits with your doctor. It is not known whether this drug passes into breast milk. Breast-feeding is not recommended while using this drug. Consult your doctor before breast-feeding.

INTERACTION

Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription/herbal products you may use, especially of: carbamazepine, fluvoxamine, drugs for high blood pressure, omeprazole, drugs for Parkinson's disease, rifampin.

Report drugs that cause drowsiness such as medicine for sleep (e.g., sedatives), tranquilizers, anti-anxiety drugs (e.g., diazepam), narcotic pain relievers (e.g., codeine), psychiatric medicines (e.g., phenothiazines such as chlorpromazine, or tricyclics such as amitriptyline), anti-seizure drugs (e.g., phenytoin), muscle relaxants, antihistamines that cause drowsiness (e.g., diphenhydramine). Check the labels on all your medicines (e.g., cough-and-cold products) because they may contain ingredients that cause drowsiness. Ask your pharmacist about the safe use of those products. Do not start or stop any medicine without doctor or pharmacist approval.

DRUG DESCRIPTION

Olanzapineis an a typical antipsychoticfor the treatment of: schizophreniadepressive episodes associated with bipolar disorder, as part of the Symbyax formulationacute manic episodes and maintenance treatment in bipolar disorder.

Olanzapine is a yellow crystalline solid, which is practically insoluble in water.Each tablet contains olanzapine equivalent to 2.5 mg (8 µmol), 5 mg (16 µmol), 7.5 mg (24 µmol), 10 mg (32 µmol), 15 mg (48 µmol), or 20 mg (64 µmol). Inactive ingredients are carnauba wax, crospovidone, hydroxypropyl cellulose, hypromellose, lactose, magnesium stearate, microcrystalline cellulose, and other inactive ingredients.

Olanzapine is a medication that is used to treat schizophrenia and acute manic episodes associated with bipolar I disorder. Olanzapine belongs to a drug class known as atypical antipsychotics. Other members of this class include clozapine (Clozaril), risperidone (Risperdal), aripiprazole (Abilify) and ziprasidone (Geodon). The exact mechanism of action of olanzapine is not known. It may work by blocking receptors for several neurotransmitters (chemicals that nerves use to communicate with each other) in the brain. It binds to alpha-1, dopamine, histamine H-1, muscarinic, and serotonin type 2 (5-HT2) receptors.

Note /Government Notification: These chemicals are designated as those that are used in the manufacture of the controlled substances and are important to themanufacture of the substances. For any (Control Substance) products Import and Export *** subjected to your country government laws /control substance ACT.

Information: The information on this web page is provided to help you to work safely, but it is intended to be an overview of hazards, not a replacement for a full Material Safety Data Sheet (MSDS). MSDS forms can be downloaded from the web sites of many chemical suppliers. ,also that the information on the PTCL Safety web site, where this page was hosted, has been copied onto many other sites, often without permission. If you have any doubts about the veracity of the information that you are viewing, or have any queries, please check the URL that your web browser displays for this page. If the URL begins "www.tajapi.com/www/Denatonium Benzoate.htm/" the page is maintained by the Safety Officer in Physical Chemistry at Oxford University. If not, this page is a copy made by some other person and we have no responsibility for it.

The Controlled Substances Act (CSA) was enacted into law by the Congress of the United States as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970.[1] The CSA is the federal U.S. drug policy under which the manufacture, importation, possession, use and distribution of certain substances is regulated. The Act also served as the national implementing legislation for the Single Convention on Narcotic Drugs

This document plus the full buyer/ prescribing information, prepared for health professionals can be found at:
http://www.tajapi.com
or by contacting the sponsor, Taj Pharmaceuticals Limited., at:
91 022 30601000.
This leaflet was prepared by
Taj Pharmaceuticals Limited,
Mumbai (India).
MPSTJ278
Last revised: 29 August 2009